Get a Special Discount on the Oxford Income Letter: https://www.marketbeat.com/y/yt978/
Drug prices are back in the headlines, but the healthcare and biotech sector has been quietly delivering some of the strongest returns in the market this year, including one name up nearly 500% in a year. Marc Lichtenfeld of the Oxford Club joins the show to break down why healthcare tends to be interest rate neutral and share his top three picks: a short-term technical setup, a mid-term catalyst play, and a long-term dividend growth story.
Lichtenfeld covers chart patterns, short interest and squeeze potential, upcoming phase three trial data, and why some biotech names get acquired at massive premiums, plus why blue-chip pharma can offer both growth and reliable dividend increases.
Let me know in the comments which of these three picks you're most interested in. 📲 Text 'YouTube' to 68285 for FREE SMS breaking news alerts on top stocks.
DISCLAIMER: MarketBeat's videos are for educational and informational purposes only and do not constitute financial, legal, or tax advice. We are not registered investment advisers, and nothing herein is a recommendation to buy, sell, or hold any security or strategy. Investing involves risk—including the potential loss of principal—so always perform your own due diligence and consult a licensed professional before acting. All opinions are those of the presenters and may change without notice. Presenters and MarketBeat personnel may own or trade the securities discussed. Past performance is not indicative of future results; any examples or case studies shown are illustrative and not typical. Some links or promotions mentioned may be affiliate partnerships that compensate MarketBeat at no additional cost to you. MarketBeat and its representatives accept no liability for any losses arising from reliance on this content.
Podden och tillhörande omslagsbild på den här sidan tillhör
MarketBeat. Innehållet i podden är skapat av MarketBeat och inte av,
eller tillsammans med, Poddtoppen.
